Initial McGill experience with fluorodeoxyglucose PET/CT staging of soft-tissue sarcoma

Current Oncology

Volumn 17, Issue 6, 2010, Pages 18-22

  Roberge, D ^a   Hickeson, M ^a   Charest, M ^b   Turcotte, R E ^a  

^a MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^b Lakeshore General Hospital   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE; MEDRONATE TECHNETIUM TC 99M;

ADOLESCENT; AGED; ANAMNESIS; BONE METASTASIS; BONE SCINTISCANNING; CANCER LOCALIZATION; CANCER STAGING; CANCER SURGERY; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC IMAGING; DIAGNOSTIC VALUE; EXCISION; FALSE POSITIVE RESULT; FEMALE; FOLLOW UP; HUMAN; LEIOMYOSARCOMA; LIPOSARCOMA; LUNG METASTASIS; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; METASTASIS; PAROTID GLAND TUMOR; PHYSICAL EXAMINATION; POSITRON EMISSION TOMOGRAPHY; PRIMARY TUMOR; RETROSPECTIVE STUDY; REVIEW; SOFT TISSUE SARCOMA; SYNOVIAL SARCOMA;

EID: 78650100307     PISSN: None     EISSN: 17187729     Source Type: Journal    
DOI: 10.3747/co.v17i6.538     Document Type: Review

References (12)

1. Mariani L, Miceli R, Kattan MW, et al. Validation and adaptation of a nomogram for predicting the survival of patients Soft-tissue sarcoma, positron-emission tomography, staging with extremity soft tissue sarcoma using a three-grade system. Cancer 2005;103:402-8.
2. Potter DA, Glenn J, Kinsella T, et al. Patterns of recurrence in patients with high-grade soft-tissue sarcomas. J Clin Oncol 1985;3:353-66.
3. King DM, Hackbarth DA, Kilian CM, Carrera GF. Soft-tissue sarcoma metastases identifed on abdomen and pelvis ct imaging. Clin Orthop Relat Res 2009;467:2838-44.
4. Conill C, Setoain X, Colomo L, et al. Diagnostic effcacy of bone scintigraphy, magnetic resonance imaging, and positron emission tomography in bone metastases of myxoid liposar-coma. J Magn Reson Imaging 2008;27:625-8.
5. Hicks RJ, Toner GC, Choong PF. Clinical applications of molecular imaging in sarcoma evaluation. Cancer Imaging 2005;5:66-72.
6. Benz MR, Czernin J, Allen-Auerbach MS, et al. fd g -pet /c t imaging predicts histopathologic treatment responses after the initial cycle of neoadjuvant chemotherapy in high-grade soft-tissue sarcomas. Clin Cancer Res 2009;15:2856-63.
7. 18F Fluorodeoxyglucose positron emission tomography as a predictor of pathologic grade and other prognostic variables in bone and soft tissue sarcoma. Clin Cancer Res 2000;6:1279-87.
8. Bastiaannet E, Groen H, Jager PL, et al. The value of fd g -p e t in the detection, grading and response to therapy of soft tissue and bone sarcomas; a systematic review and meta-analysis. Cancer Treat Rev 2004;30:83-101.
9. Tateishi U, Yamaguchi U, Seki K, Terauchi T, Arai Y, Kim EE. Bone and soft-tissue sarcoma: preoperative staging with fuor-ine 18 fuorodeoxyglucose pet /c t and conventional imaging. Radiology 2007;245:839-47.
10. Iagaru A, Quon A, McDougall IR, Gambhir SS. F-18 fdgpe t/ct evaluation of osseous and soft tissue sarcomas. Clin Nucl Med 2006;31:754-60.
11. Piperkova E, Mikhaeil M, Mousavi A, et al. Impact of pet and c t in pe t /c t studies for staging and evaluating treatment response in bone and soft tissue sarcomas. Clin Nucl Med 2009;34:146-50.
12. De Wever W, Meylaerts L, De Ceuninck L, Stroobants S, Verschakelen JA. Additional value of integrated pet -c t in the detection and characterization of lung metastases: correlation with c t alone and pet alone. Eur Radiol 2007;17:467-73.